Programs

Attune Pharmaceuticals remains at the forefront of talent development in biopharma by offering structured, role-aligned onboarding and learning programs. Our dual-track model—On-Site Intern Training and the Clinical Cognition Assessment Protocol (CCAP)—ensures every professional is operationally capable, security-aware, and aligned with our regulated ecosystem from day one.

Hereditary Angiodema (HAE)

Attune Pharmaceuticals is advancing therapies for Hereditary Angiodema (HAE), a rare and potentially life-threatening genetic condition characterized by recurring episodes of severe swelling.

Paroxysmal Nocturnal Hemoglobinuria (PNH)

Paroxysmal Nocturnal Hemoglobinuria (PNH) is an ultra-rare and life-threatening disease resulting from the chronic hemolysis of a patient’s red blood cells (RBCs).

Complement Pathway Inhibition

We've discovered small molecule inhibitors targeting complement system dysregulation in rare diseases.

On-Site Intern Training

This immersive program trains early-career professionals on:

  • Clinical trial administration & documentation
  • HIPAA- and GLP-compliant data integrity
  • Quality assurance procedures
  • Chain-of-command collaboration
Remote Onboarding Assessment (CCAP)

The CCAP is a secure, simulation-based remote screening protocol evaluating:

  • Secure credential handling
  • Protocol adherence
  • HIPAA-compliant decision-making
  • Check generation and procurement workflows